Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETOP 14-18 CHESS
2024-511134-12-00Phase 2Authorised
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Sep 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of durvalumab and tiragolumab in non-small cell lung cancer (NSCLC), sponsored by ETOP IBCSG Partners Foundation. Primary endpoint: Progression-free survival at 1 year. Planned start Sep 2024; status: authorised.
02
Drugs
durvalumabtiragolumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-511134-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511134-12-00.